Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022
- Published Date: Feb 2018
- Pages: 75
- Format: PDF
- Report ID: PM1106
- Base Year: 2016
- Historical Data: 2015-2016
Request for Sample
Please fill out the form to receive sample pages of the report
License and Pricing
Purchase Report Sections
- Regional analysis
- Segmentation analysis
- Industry outlook
- Competitive landscape
Connect With Experts
Suggested Report
- Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Liver Disease Diagnostics Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Astaxanthin Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- CBD Nutraceuticals Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
Global Dermatology Drugs Market Size & Share - Industry Report, 2022